Category
Blog
-
2023
-
NICE Recommends Upstaza for Rare Genetic Disorder
-
Incyte Gets CRL for Jakafi Extended-Release Tablets
-
Glenmark Pharmaceuticals’ Generic of Leo Pharma’s Enstilar Approved
-
Cyclerion’s Mitochondrial Diseases Candidate Gets Orphan Drug Nod
-
AstraZeneca, Amgen’s asthma launch Tezspire picks up backing from England’s NICE
-
Enrollment and Topline Data Expected Sooner for Phase 3 Trial of Pitolisant in Idiopathic Hypersomnia
-
Caribou’s CAR-T cell therapy receives fast track status
-
Signs of change in Korean diabetes treatment market
-
Merck, Eisai decide to discontinue advanced melanoma therapy trial
-
US FDA advisers to weigh full approval for Eisai-Biogen’s Alzheimer’s drug